Research Articles | Page 25 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Parsing the Paradox of Myelodysplastic Syndromes Dec 2020 Journal of clinical oncology: official journal of the American Society Clinical Oncologysd Myelodysplastic Syndromes (MDS)
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study Apr 2023 Journal of Hematology & Oncology Myelodysplastic Syndromes (MDS)
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes Apr 2024 Journal of Internal Medicine Myelodysplastic Syndromes (MDS)
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs Dec 2020 Journal of Managed care and specialty pharmacy Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease Dec 2020 Journal of Managed care and specialty pharmacy Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology Dec 2020 Journal of Managed care and specialty pharmacy Paroxysmal Nocturnal Hemoglobinuria (PNH)
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes Aug 2020 Journal of Patient-Reported Outcomes Myelodysplastic Syndromes (MDS)
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review Jan 2024 Journal of Women's Health Paroxysmal Nocturnal Hemoglobinuria (PNH)
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? Jun 2023 Lancet Myelodysplastic Syndromes (MDS)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jun 2023 Lancet Myelodysplastic Syndromes (MDS)